摘要
目的探讨年龄与性别对高心血管风险的2型糖尿病和心力衰竭患者心内科门诊用药的影响。方法检索2022年4月至2023年11月某三甲医院门诊处方含二甲双胍、胰岛素、钠-葡萄糖共转运蛋白2抑制剂(SGLT2i)、沙库巴曲缬沙坦和血管紧张素Ⅱ受体拮抗剂(ARB)的患者信息,从年龄、性别和诊断分析处方。结果ARB类、沙库巴曲缬沙坦、SGLT2i、二甲双胍和胰岛素的处方量分别为15103、8403、2120、1541和607。从性别上分,各类药物治疗患者的男性比例均多于女性。其中,SGLT2i治疗的患者男女占比分别为63.58%和36.42%,ARB类药物治疗的患者男女占比分别为53.66%和46.34%。与二甲双胍、胰岛素、沙库巴曲缬沙坦和ARB类药物治疗的患者相比,SGLT2i治疗的男性患者明显多于女性(P<0.05)。从年龄上分,各药物治疗患者18~40岁的比例最低,66岁及以上比例最高(ARB类药物治疗患者除外)。与沙库巴曲缬沙坦或ARB治疗的患者相比,SGLT2i治疗的>40~<66岁和66岁及以上患者表现为男性明显多于女性。将诊断限制在含心脏疾病的处方后,与沙库巴曲缬沙坦或ARB类药物治疗患者相比,SGLT2i治疗的40岁以上患者仍表现为男性明显多于女性(P<0.05)。结论在心内科就诊的患者中,性别(女性且年龄大于40岁)可能已经成为接受SGLT2i药物治疗的障碍。这可能造成部分女性患者未能获得进一步的心血管保护。
Objective To explore the influence of age and gender on outpatient medication in patients with high cardiovascular risk type 2 diabetes and heart failure.Methods The information of patients with metformin,insulin,SGLT2i,sacubitril-valsartan and ARB drugs prescribed in the outpatient department of a tertiary hospital from April 2022 to November 2023 was retrieved and analyzed by age,gender and diagnosis.Results Prescriptions for ARB,sacubitril-valsartan,SGLT2i,metformin,and insulin were 15103,8403,2120,1541,and 607,respectively.In terms of gender,the proportion of male patients with all types of drug treatment was higher than that of female patients.Among them,the proportion of male and female patients treated with SGLT2i was 63.58%and 36.42%,and the proportion of male and female patients treated with ARB drugs was 53.66%and 46.34%,respectively.Compared with patients treated with metformin,insulin,sacubitril-valsartan and ARB,SGLT2i treatment had significantly more male patients than female patients(P<0.05).In terms of age,the proportion of patients aged 18 to 40 years was the lowest,and the proportion of patients aged 66 years and older was the highest(except for patients treated with ARB drugs).Compared to patients treated with sacubitril-valsartan or ARB,SGLT2i treatment for patients aged>40-<66 years and 66 and above showed significantly more male than female patients.After limiting diagnoses to prescriptions containing heart disease,patients over 40 years of age treated with SGLT2i continued to present significantly more men than women compared with patients treated with sacubitril-valsartan or ARB(P<0.05).Conclusions In department of cardiology,the gender(female,older than 40 years)of patients may have been a barrier to receiving SGLT2i drug therapy.This may result in some female patients not receiving further cardiovascular protection.
作者
冯晓俊
张炀
邓明影
倪夏昀
解勇圣
张蕾
FENG Xiaojun;ZHANG Yang;DENG Mingying;NI Xiayun;XIE Yongsheng;ZHANG Lei(Department of Pharmacy,the First Affiliated Hospital of University of Science and Technology of China,Anhui Provincial Key Laboratory of Precision Medicine Preparation and Clinical Pharmacy,Hefei 230001,China)
出处
《中国临床保健杂志》
CAS
2024年第3期333-336,共4页
Chinese Journal of Clinical Healthcare
基金
国家自然科学基金面上项目(52373160)。
关键词
糖尿病
2型
心力衰竭
心脏病危险因素
门诊医疗
年龄因素
性别因素
Diabetes mellitus,type 2
Heart failure
Heart disease risk factors
Ambulatory care
Age factors
Sex factors
